Eileen Comia, MD
Internal Medicine · Bloomfield, CTNPI 1235233313
Payments from drug & device makers
Across 74 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$457
- Pfizer$218
- Amarin Pharma, Inc.$147
- Exact Sciences$91
- Johnson & Johnson$79
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$73
- plus $299 from 12 others
What the payments were for
- Food & beverage$1,363100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $457 |
| Pfizer | 11 | $218 |
| Amarin Pharma, Inc. | 8 | $147 |
| Exact Sciences | 4 | $91 |
| Johnson & Johnson | 4 | $79 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| AstraZeneca | 4 | $61 |
| Lilly USA, LLC | 2 | $48 |
| Novo Nordisk | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $19 |
| Abbott | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Mylan Specialty L.p. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$1,363 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $6,393 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $1,792 |
| Atorvastatin Calcium | 50 | $413 |
| Amlodipine Besylate | 157 | $384 |
| Carvedilol | 48 | $348 |
| Lisinopril | 51 | $337 |
| Doxazosin Mesylate | 19 | $295 |
| Clonazepam | 14 | $246 |
| Glipizide ErGlipizide | 13 | $241 |
| Metoprolol Succinate | 44 | $241 |
| Rosuvastatin Calcium | 17 | $230 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $227 |
| Levothyroxine Sodium | 58 | $200 |
| Losartan Potassium | 51 | $186 |
| Omeprazole | 17 | $183 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Bloomfield
- Bechara BarrakBloomfield$30K
- John WenceslaoBloomfield$30K
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.